EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Polyadenylic-polyuridylic acid plus locoregional radiotherapy versus chemotherapy with CMF in operable breast cancer: A 14 year follow-up analysis of a randomized trial of the Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC)



Polyadenylic-polyuridylic acid plus locoregional radiotherapy versus chemotherapy with CMF in operable breast cancer: A 14 year follow-up analysis of a randomized trial of the Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC)



Breast Cancer Research and Treatment 64(2): 189-191



With a median follow-up of 14 years, the combination of polyadenylic-polyuridylic acid plus locoregional radiotherapy (257 patients) has significantly improved disease-free survival (p = 0.03) and significantly reduced the incidence of metastases (p = 0.04) when compared to CMF alone (260 patients), in women with operable breast cancer.

(PDF emailed within 1 workday: $29.90)

Accession: 011164313

Download citation: RISBibTeXText



Related references

Polyadenylic-polyuridylic acid plus locoregional radiotherapy versus chemotherapy with CMF in operable breast cancer: a 14 year follow-up analysis of a randomized trial of the Fédération Nationale des Centres de Lutte contre le Cancer (FNCLCC). Breast Cancer Research and Treatment 64(2): 189-191, 2001

Polyadenylic-polyuridylic acid plus locoregional and pelvic radiotherapy versus chemotherapy with CMF as adjuvants in operable breast cancer. A 6 1/2 year follow-up analysis of a randomized trial of the French Federation of Cancer Centers (F.F.C.C.). Breast Cancer Research and Treatment 19(1): 15-21, 1991

Polyadenylic polyuridylic acid plus locoregional and pelvic radiotherapy versus chemotherapy with cmf as adjuvants in operable breast cancer a 6 and one half year follow up analysis of a randomized trial of the french federation of cancer centers ffcc. Breast Cancer Research & Treatment 19(1): 15-22, 1991

Polyadenylic polyuridylic acid a u plus radiotherapy rx versus chemotherapy with cmf as adjuvant in operable breast cancer a 6 1 2 year follow up analysis of a randomized trial of the french federation of cancer centers ffcc. Breast Cancer Research & Treatment 16(2): 191, 1990

Radiotherapy and chemotherapy for invasive thymomas: a multicentric retrospective review of 90 cases. The FNCLCC trialists. Fédération Nationale des Centres de Lutte Contre le Cancer. International Journal of Radiation Oncology, Biology, Physics 32(3): 651-659, 1995

Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC). International Journal of Cancer 76(3): 325-330, 1998

Randomized Multicenter and Stratified Phase II Study of Gemcitabine Alone Versus Gemcitabine and Docetaxel in Patients with Metastatic or Relapsed Leiomyosarcomas A Federation Nationale des Centres de Lutte Contre le Cancer FNCLCC French Sarcoma Group. 2012

Conformal radiation therapy. Fédération nationale des centres de lutte contre le cancer (FNCLCC). Bulletin du Cancer 82(5): 325-330, 1995

Primary cerebral lymphomas: unsolved issues regarding first-line treatment, follow-up, late neurological toxicity and treatment of relapses. The FNCLCC. French Fédération Nationale des Centres de Lutte contre le Cancer. Annals of Oncology 11 Suppl 1(): 39-44, 2000

Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). Oncologist 17(9): 1213-1220, 2013

Chemoprevention of cancer of the breast. Position statement on July 3, 1998 of the Fédŕation Nationale des Centres de Lutte Contre le Cancer (FNCLCC). Bulletin du Cancer 85(8): 725-725, 1998

ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. GETCB (Groupe d'Etude et Traitement des Cancers Bronchiques), FNCLCC (Féderation Nationale des Centres de Lutte contre le Cancer) and the CEBI trialists. International Journal of Radiation Oncology, Biology, Physics 20(6): 1183-1190, 1991

Recommendations for anatamo-pathologic management of soft tissue sarcomas in the adult. Pathologists of the FNCLCC Sarcoma Group (Fédération Nationale des Centres de Lutte Contre le Cancer). Annales de Pathologie 18(6): 505-511, 1999

Thymoma: results of a multicentric retrospective series of 149 non-metastatic irradiated patients and review of the literature. FNCLCC trialists. Fédération Nationale des Centres de Lutte Contre le Cancer. RadioTherapy and Oncology 34(1): 9-16, 1995

Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. Journal of Clinical Oncology 23(22): 4881-4887, 2005